Stockreport

CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis

CymaBay Therapeutics Inc.  (CBAY) 
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cymabay.com
PDF NEWARK, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and provi [Read more]